<SEC-DOCUMENT>0001104659-21-076746.txt : 20210604
<SEC-HEADER>0001104659-21-076746.hdr.sgml : 20210604
<ACCEPTANCE-DATETIME>20210604090601
ACCESSION NUMBER:		0001104659-21-076746
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210604
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210604
DATE AS OF CHANGE:		20210604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36598
		FILM NUMBER:		21995076

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(608) 441-8120

	MAIL ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2118519d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT>Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>June 4, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>CELLECTAR
BIOSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT>(<I>Exact name of registrant as specified in its charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; font-size: 10pt; font-weight: bold; text-align: center">Delaware</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt; font-weight: bold; text-align: center">1-36598</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt; font-weight: bold; text-align: center">04-3321804</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: center">(State or other jurisdiction<BR>
 of incorporation)</TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: center">(Commission<BR>
 File Number)</TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: center">(I.R.S. Employer <BR>
Identification No.)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>100
Campus Drive, Florham Park, New Jersey 07932</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT>(<I>Address of principal executive offices, and zip code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(608)
441-8120</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT>(<I>Registrant's telephone number, including area code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.00001</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLRB</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ Capital Market</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM 7.01&nbsp;</B></FONT></TD>
    <TD STYLE="width: 87%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGULATION FD
DISCLOSURE</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On June 4,
2021, we </FONT>issued a press release announcing that we presented a poster at the American Society of Clinical Oncology (ASCO) Annual
meeting. In conjunction with the poster presentation, our management will host a KOL call with the lead investigator for our Phase 2 CLOVER-1
study of CLR 131 in patients with relapsed/refractory B-cell hematologic cancers, Dr. Sikander Ailawadhi, M.D. of the Mayo Clinic. A copy
of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM 9.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL STATEMENTS AND EXHIBITS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 75%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="tm2118519d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><A HREF="tm2118519d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated June 4, 2021, titled &ldquo;Cellectar Presents Data in Waldenstrom&rsquo;s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dated: June 4, 2021</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CELLECTAR BIOSCIENCES, INC.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"> /s/ Dov Elefant</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 42%">Dov Elefant</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Financial Officer</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2118519d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><IMG SRC="tm2118519d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>Cellectar Presents
Data in Waldenstrom&rsquo;s Macroglobulinemia in Poster at</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>the 2021 American Society
of Clinical Oncology (ASCO) Annual Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>Mean treatment free
remission 1.1 years and remains ongoing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>Progression free survival
for MYD88 wild type and high-risk patients 18 months and ongoing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FLORHAM
PARK, N.J., June 4, 2021</B></FONT> --&nbsp;Cellectar Biosciences, Inc.&nbsp;(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company
focused on the discovery and development of drugs for the treatment of cancer, today presented a poster at the American Society of Clinical
Oncology (ASCO) Annual meeting. In conjunction with the poster presentation, management will host a KOL call with the lead investigator
for the company&rsquo;s Phase 2 CLOVER-1 study of CLR 131 in patients with relapsed/refractory B-cell hematologic cancers, Dr. Sikander
Ailawadhi, M.D. of the Mayo Clinic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
poster presentation entitled: </FONT><I><U>Treatment Free Remission (TFR) and Overall Response Rate (ORR) Results in Patients with Relapsed/Refractory
Waldenstrom&rsquo;s Macroglobulinemia (WM) Treated with CLR 131</U></I> is an in-depth update of six patients from the company&rsquo;s
Phase 2a study of CLR 131 in Waldenstrom&rsquo;s macroglobulinemia. To date, data have shown:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">100% (6/6) overall response rate, 83.3% (5/6) major response rate and a 16.7% (1/6) complete response
rate</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Median time to initial response was 22 days after first infusion</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Median time to major response, as defined as at least a 50% reduction in IgM, was 44 days after first
infusion</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Mean treatment free remission, as defined as the time from the last CLR 131 infusion to progression of
disease, is 1.1 years and remains ongoing</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Duration of response has not been reached, with 100% of the MYD88 wild type and high risk patients exceeding
8.5 months</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Progression free survival (PFS) for both MYD88 wild type patients as well as the high-risk subgroup has
not been reached after 18 months; PFS for multidrug refractory patients was 11 months</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The most frequently reported treatment emergent adverse events were cytopenias</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&ldquo;CLR 131 is a differentiated
targeted radiotherapy that has the potential to address patients with any mutational status, risk profile or multi-drug refractoriness
in WM. Our pivotal study strategy will leverage these properties to address the treatment needs of patients, including the potential to
provide durable response rates and meaningful treatment-free remission,&rdquo; said Dr. John Friend, chief medical officer at Cellectar.
 &ldquo;CLR 131 has demonstrated impressive results including, to our knowledge, the only monotherapy to result in a complete response
in this challenging WM patient set.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">James Caruso, president
and CEO of Cellectar added, &ldquo;The data presented today from our ongoing Phase 2 CLOVER-1 study of CLR 131 in Waldenstrom&rsquo;s
further validates our clinical development program and gives us confidence in our goal of providing a new and better treatment with the
potential to prolong and improve the quality of life for patients suffering from this devastating disease.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
will host a conference call and webcast today, June 4, at 10:00 am ET featuring key opinion leader Dr. Sikander Ailawadhi. </FONT>Dr.
Ailawadhi is a Professor of Medicine, Lead, International Cancer Center, Division of Hematology/Oncology, Departments of Medicine and
Cancer Biology at Mayo Clinic Florida. He was awarded the 2013 NCI Cancer Clinical Investigator Team Leadership Award as an Assistant
Professor of Medicine at the USC Norris Comprehensive Cancer Center. Subsequently, he joined the Division of Hematology and Oncology at
Mayo Clinic in Florida as a Senior Consultant in order pursue his career goal of clinical, translational and outcomes-based research in
B-cell malignancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Dial-in &amp; Webcast information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Domestic:</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">877-705-6003</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">International:</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">201-493-6725</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: left">Conference ID:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; text-align: left">13719983</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Webcast:</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><U>http://public.viavid.com/index.php?id=145036</U></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
replay of the call will be available on the </FONT><U>Events</U> page of company website following the live event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About the Pivotal
Trial of CLR 131 in Waldenstrom&rsquo;s macroglobulinemia (WM)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The pivotal trial is
designed as a global, non-comparator, single arm, expansion cohort of the currently ongoing Phase 2 CLOVER-1 study of CLR 131. The study
will enroll 50 WM patients. Patients in the trial will receive up to four doses of CLR 131 over two cycles (cycle one days 1, 15, and
cycle two days 57, 71). The primary endpoint of the trial is response rate as defined as a partial response (a minimum of a 50% reduction
in the biological marker IgM) or better in patients that receive a minimum total body dose of 60 mCi with secondary endpoints of treatment
free survival, duration of response and progression free survival. An independent data monitoring committee (iDMC) will perform an interim
safety and futility evaluation on the first 10 patients enrolled. The assessment will occur patient by patient and&nbsp;will conclude
after the tenth patient is evaluated; there is&nbsp;no planned study stoppage.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About Waldenstrom&rsquo;s
macroglobulinemia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Waldenstrom&rsquo;s macroglobulinemia
(WM) is a rare and incurable disease defined by specific genotypic subtypes that defines patient responses and long-term outcomes. The
annual incidence is 6,500 with prevalence of approximately 60,000 patients globally. WM is a lymphoma, or cancer of the lymphatic system.
The disease occurs in a type of white blood cell called a B-lymphocyte or B-cell, which normally matures into a plasma cell whose job
is to manufacture immunoglobulins (antibodies) to help the body fight infection. In WM, there is a malignant change to the B-cell in the
late stages of maturing, and it continues to proliferate into a clone of identical cells, primarily in the bone marrow but also in the
lymph nodes and other tissues and organs of the lymphatic system. These clonal cells over-produce an antibody of a specific class called
IgM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">WM cells have characteristics
of both cancerous B-lymphocytes (NHL) and plasma cells (multiple myeloma), and they are called lymphoplasmacytic cells. For that reason,
WM is classified as a type of non-Hodgkin&rsquo;s lymphoma called lymphoplasmacytic lymphoma (LPL). About 95% of LPL cases are WM; the
remaining 5% do not secrete IgM and consequently are not classified as WM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">There is no standard
treatment for WM. Several drugs have demonstrated activity either alone or in combinations, but only a single drug has received regulatory
approval. Treatment is mainly focused on the control of symptoms and the prevention of organ damage. Front-line treatments for WM include
rituximab alone or in combination with other agents. In the salvage therapy (second line or later) setting, ibrutinib, combinations of
proteosome inhibitors and immunomodulatory drugs and stem cell transplantation are considered. Ibrutinib is the only drug to receive regulatory
approval (2015) as a salvage therapy; in late 2019, it was approved for front-line treatment in combination with rituximab. Factors such
as long-term cytopenias, age, hyper viscosity, the need for quick disease control, lymphadenopathy, co-morbidities, and IgM-related end-organ
damage are key consideration in the choice of treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Cellectar Biosciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Cellectar Biosciences
is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently
and through research and development collaborations. The company&rsquo;s core objective is to leverage its proprietary Phospholipid Drug
Conjugate&trade; (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better
safety as a result of fewer off-target effects. The company&rsquo;s PDC platform possesses the potential for the discovery and development
of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development
collaborations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The company&rsquo;s product
pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary preclinical
PDC chemotherapeutic programs and multiple partnered PDC assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, please visit</FONT> <U>www.cellectar.com</U> or join the conversation by liking and following us on the company&rsquo;s
social media channels: <U>Twitter</U>, <U>LinkedIn</U>, and <U>Facebook</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statement Disclaimer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This news release contains
forward-looking statements. You can identify these statements by our use of words such as &quot;may,&quot; &quot;expect,&quot; &quot;believe,&quot;
 &quot;anticipate,&quot; &quot;intend,&quot; &quot;could,&quot; &quot;estimate,&quot; &quot;continue,&quot; &quot;plans,&quot; or their
negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current
beliefs and expectations as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery
and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties related to any potential disruptions at our sole source supplier of
CLR 131, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical
development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation,
our ability to maintain orphan drug designation in the United States for CLR 131, the volatile market for priority review vouchers, our
pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical
companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is
contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December
31, 2020. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Investors:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Monique Kosse</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Managing Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">212-915-3820</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>monique@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2118519d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2118519d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !+ .P# 2(  A$! Q$!_\0
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M^;\4<KSC#QJ_#:-_3F=_P/Z:*_%#_@J-_P %)_B5XU_:L\4>&O#'BOQ%X/\
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MY]OLGX:Z!X9\*>#K?2_!]EH6F^'],DFM+>ST:&*&SM'CF=)HE2(!$*RB164
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,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
